At Lonza we always welcome interest and inquiries from the media about our business, services and capabilities. Please use the resources on this page, or contact our media relations team for specific inquiries, and we will connect you to the appropriate business leader or subject matter expert.

18 May 2021
Lonza Launches Next Generation 4D-Nucleofector Cell Transfection Platform with...
Lonza launches next-generation 4D-Nucleofector® Platform, the leading non-viral cell transfection method for a wide variety of cell types – even those traditionally hard to...
17 November 2021
Lonza and BlueJay Therapeutics Announce Manufacturing Agreement for its Antibody...
Lonza to provide a program tailored to Bluejay's needs to enable manufacturing of BJT-778 Collaboration to provide BlueJay access to cell line construction, process...
12 October 2021
Capital Markets Day 2021: Lonza to Capture Market Demand and Ensure Sustainable...
At its Capital Markets Day, Lonza outlined strategic priorities and innovation highlights with a clear focus on sustainable value creation Accelerated, de-risked, long-term...